A case of acute myeloid leukemia with mast cell differentiation (AML-MC) that subsequently fulfilled diagnostic criteria for mast cell leukemia (MCL), an aggressive type of systemic mastocytosis (SM), ...

A comprehensive map of aberrant hematopoiesis in people with acute myeloid leukemia defines specific cell states and potential therapeutic targets. The team used their reference map for normal ...

Chronic myeloid leukemia (CML) is a hematopoietic malignancy characterized by BCR-ABL1 gene fusion. The immune microenvironment, implicated in relapse and drug resistance, poses significant challenges ...

Chronic myeloid leukemia may seem to appear suddenly, but new research shows it begins years before diagnosis with an explosive surge of growth. Scientists tracked how a single genetic accident—the ...

Chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL) are two different types of leukemia. Both conditions affect white blood cells. CML affects a type of white blood cell called ...

The choice of frontline therapy for a patient with chronic phase chronic myeloid leukemia (CP-CML) can have a profound effect on the long-term clinical outcome. Currently, five tyrosine kinase ...

A study revealed that RBPMS supports leukemia cell survival and progression. The protein upregulates FOXO1, leading to increased glycolysis in AML cells. Inhibiting RBPMS holds potential as a ...

Lead CML researcher discusses the evolution of a groundbreaking treatment and its effect on patient survival. When imatinib (Gleevec; Novartis), the first-ever tyrosine kinase inhibitor, made its ...